VKH
CNCR

Virtu KCG Holdings’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Virtu KCG Holdings’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-34,235
Closed -$978K – 2894
2015
Q4 		$978K Buy
+34,235
New +$985K 0.02% 879

Other funds holding CNCR

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Virtu KCG Holdings's CNCR Position: Q1 2016 in Review

Virtu KCG Holdings sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2016, closing a stake of 34,235 shares — an estimated $978K sold.

Virtu KCG Holdings first reported a position in CNCR in Q4 2015 and held it in 1 quarter. The position peaked at $978K in Q4 2015. 11 funds tracked by Wall St. Rank hold CNCR as of Q1 2016.

  • Virtu KCG Holdings reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 34,235 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2016, an estimated $978K.
  • Virtu KCG Holdings first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 1 quarter.
  • Virtu KCG Holdings's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $978K in Q4 2015.
  • 11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2016.

Based on Virtu KCG Holdings's 13F filing for Q1 2016, filed 13 May 2016.